Olivier Salvado, CSIRO, Australie This presentation will describe some of the imaging analysis research that we are conducting at CSIRO to develop new imaging biomarkers based on the AIBL study for Alzheimer’s disease. Several biomarkers can be computed such as GM volume, cortical thickness, white matter lesions from MRI, as well as PET PiB for amyloid imaging. Using both MRI and PET can provide a complementary clinical picture of the disease and provide insights into its aetiology. Special emphasis will be made on the partial volume correction of the PET PiB which is a critical methodological step, as well as the estimation of atrophy from structural MRI. Recent findings from the AIBL study will be described trying to elucidate the discrepancy between pattern of atrophy and patterns of amyloid deposition.